this is an appeal from the united states district court for the district of delaware in a patent action that vanderbilt university vanderbilt brought against icos corporation icos on july.vanderbilt filed suit under alleging that vanderbilt scientists jackie corbin corbin,sharron francis francis,and sekhar konjeti konjeti collectively the vanderbilt scientists should be added as joint inventors on patent the patent and the patent.the district court rendered its findings of fact and conclusions of law in a january,opinion.vanderbilt icos,d.the district court entered final judgment on january,concluding that vanderbilt failed to prove that the vanderbilt scientists are joint inventors of the and patents.vanderbilt appeals the district court final judgment.for the reasons stated below,we affirm.
this case involves compounds and methods for treating erectile dysfunction,including the compound known as tadalafil,a inhibitor and the active ingredient in the drug cialis.is a phosphodiesterase enzyme found in smooth muscle cells that binds to and hydrolyzes or breaks down cgmp,a cyclic nucleotide found in smooth muscle tissues.in normal function,cgmp binds with and activates a protein kinase which results in relaxation and dilation of the smooth muscle cell.inhibitors bind to and prevent it from binding with and breaking down cgmp.
corbin and francis are employed by vanderbilt university and were among the first to discover in the late.since that time,corbin and francis have worked on both the development of cgmp analogs and related research.
in december,corbin submitted a research proposal to glaxo glaxo requesting it sponsor his research to develop cgmp analogs.the proposal listed new cgmp analogs that corbin hoped would activate protein kinase.
in june,glaxo entered into an agreement with corbin through glaxo cardiovascular discovery grant program to underwrite the vanderbilt scientists research of cgmp analogs.under the agreement,the university retained ownership of intellectual property,but glaxo was granted a license agreement to any discoveries.during the three years of the program,corbin,francis,and konjeti submitted numerous presentations and progress reports to glaxo.
in november,corbin sent an abstract to glaxo disclosing his discovery that the potency of cgmp analogs is enhanced by adding a phenyl ring at the.meanwhile,the vanderbilt scientists continued to work on improving potency with new cgmp analogs.in may,however,glaxo indicated to corbin its concern that cgmp analogs do not work well as drugs and encouraged the vanderbilt scientists to shift their future focus to inhibitors.
outside of the glaxo program,the vanderbilt scientists continued to work on other research interests.in november,the vanderbilt scientists applied the results of their cgmp analog research to synthesize a new inhibitor.the vanderbilt scientists used a ibmx compound because it was a cheap and readily available inhibitor that is easily substituted at the.building upon their earlier research,the vanderbilt scientists attached a phenyl ring to the of the compound and attached an hydroxyl group at the position of the phenyl ring.by applying the results of their cgmp research to ibmx,the vanderbilt scientists created a inhibitor they thought was times more potent in inhibiting than the original ibmx molecule.corbin drafted a letter to vanderbilt general counsel disclosing possible therapeutic uses for the new ibmx analogs,including the treatment of male impotence.
in december,during discussions regarding a new research agreement,corbin mentioned vanderbilt work on inhibitors to barry ross,a scientist at glaxo on january,corbin sent a research proposal to glaxo detailing the test results of the cgmp analogs developed under the first research agreement.in the proposal,corbin also described the vanderbilt scientists ibmx analog that was more potent as a inhibitor than the original ibmx molecule.corbin explained the vanderbilt scientists overall strategy that the potencies of existing inhibitors could be enhanced by appending groups that would allow the inhibitors to more closely resemble the entire cyclic gmp molecule.corbin proposed that glaxo fund the vanderbilt scientists work on inhibitors going forward.corbin also noted in the january letter that the cg kinase has important functions other than the induction of vascular smooth muscle relaxation.male impotence was listed as an area of interest,though glaxo was not researching male impotence at the time.
on february,corbin and francis met with ross regarding the january proposal.later that month,on february,corbin sent a more detailed research proposal to ross which disclosed the exact design of the vanderbilt ibmx analog.the detailed research proposal also identified a table of ibmx and analogs that vanderbilt proposed for further testing.many of the listed compounds contain what vanderbilt now refers to as the vanderbilt structural features of vanderbilt ibmx analog.
on march and,glaxo france tested compounds for inhibition,including a compound it designated.
on april,ross forwarded copies of vanderbilt february,proposal to six glaxo scientists,including richard labaudiniere,the head of chemistry and leader of the project at glaxo france.
on april,glaxo france tested compounds for inhibition,including a compound designated.vanderbilt claims all of the tested compounds make some use of the vanderbilt structural features with of the compounds containing nearly all of the vanderbilt structural features.based on the inhibition test results,labaudiniere identified as a lead compound for further research on inhibition.labaudiniere assigned the further research to alain daugan,the named inventor on the patents at issue,as a separate study.in the course of testing various modifications to the compound between june and january,daugan discovered tadalafil,the claimed compound at issue in this case.
in,glaxo assigned to icos the rights,title,and interest in the compounds covered by the patents at issue.vanderbilt brought this suit under against icos to correct inventorship of the and patents.vanderbilt asserts that the vanderbilt scientists should be added as joint inventors.according to vanderbilt,the compound could not have been identified by labaudiniere as the lead compound without his use of the vanderbilt structural features.nor could tadalafil have been identified by daugan without his reliance on vanderbilt work.the district court held a bench trial and found in favor of icos.
in its analysis,the district court noted that,the applicable section for joint inventorship,sets no explicit lower limit on the quantum or quality of inventive contribution required for a person to qualify as a joint inventor.vanderbilt icos,d,quoting fina oil chem.ewen.the district court further noted that a person is a joint inventor only if he contributes to the conception of the claimed invention.id.quoting eli lilly aradigm.after a summary of the law regarding conception of chemical compounds,the district court concluded that conception of a chemical substance includes knowledge of both the specific chemical structure of the compound and an operative method of making it and does not occur unless one has a mental picture of the structure of the chemical.id.quoting burroughs wellcome barr,and amgen,chugai pharm.the district court determined that the vanderbilt scientists could not be because they never conceived the specific chemical structure of the compound claimed or the compound with all of its components.id.at citations omitted.
to guide its analysis,the district court reviewed our decision in american bioscience and concluded the case contained similar facts and thus controlled its decision.id.at.the district court recognized that in american bioscience we declined to add inventors who provided the starting materials for a chemical compound.see bd.of educ.ex rel.bd.of trustees of.state am.bioscience,american bioscience.the district court found that t he vanderbilt structural features constitute no more than a specific portion of a claimed compound in the language of american bioscience.vanderbilt,d at.
the district court concluded that b ecause there is no evidence that the vanderbilt scientists ever conceived the specific chemical structure of the compound claimed,burroughs wellcome,at,or the compound with all of its components,american bioscience,at,or communicated that compound to glaxo,plaintiff has failed to demonstrate by clear and convincing evidence,that corbin,francis and konjeti are coinventors of the patents at issue.id.the district court noted that even if the court were to find that plaintiff disclosure of the vanderbilt structural features led to the identification of and the subsequent discovery of tadalafil,american bioscience precludes the result plaintiff seeks namely,that the contribution of a molecular scaffold in the context of one molecule renders the disclosing party or parties inventors of a different family of molecules containing the same scaffold.id.at.
even after reaching the conclusion that its decision was bound by american bioscience,the district court provided a detailed analysis of the remaining facts of the case.first,the court noted that t his is not to say that corbin,francis,and konjeti did not make contributions to daugan inventive process only that,under the applicable law,these contributions fall more into the category of prosaic contributions because they did not conceive the invention as claimed.id.at.after again reviewing the conflicting stories of the parties,the district court alternatively noted that the court views plaintiff theory and defendant story equally plausible with respect to the identification of.id.at.also,in the absence of any evidence of collaboration between the vanderbilt scientists and daugan,the district court rejected vanderbilt claim to have contributed to daugan identification of tadalafil.id.at.
we begin by reviewing our case law on joint inventorship.the statutory requirements for joint inventorship are found in which states,in pertinent part 
when an invention is made by two or more persons jointly,they shall apply for patent jointly and each make the required oath,except as otherwise provided in this title.inventors may apply for a patent jointly even though they did not physically work together or at the same time,each did not make the same type or amount of contribution,or each did not make a contribution to the subject matter of every claim of the patent.
section was amended,in relevant part,in to clarify the law of joint inventorship by codifying the principles set forth in monsanto kamp.see proctor gamble distrib.the court in monsanto stated 
a joint invention is the product of collaboration of the inventive endeavors of two or more persons working toward the same end and producing an invention by their aggregate efforts.to constitute a joint invention,it is necessary that each of the inventors work on the same subject matter and make some contribution to the inventive thought and to the final result.each needs to perform but a part of the task if an invention emerges from all of the steps taken together.it is not necessary that the entire invention concept should occur to each of the joint inventors,or that the two should physically work on the project together.one may take a step at one time,the other an approach at different times.
monsanto.at.
in,we applied section to a situation where proctor gamble wished to attribute inventor status to one of its employees who did not collaborate with the named inventor.at.while both employees worked on the same subject matter,the court noted that the named inventor worked alone and was completely unaware of earlier work done by other employees.id.at.the court reviewed the amendments and monsanto and stated that 
for persons to be joint inventors under section,there must be some element of joint behavior,such as collaboration or working under common direction,one inventor seeing a relevant report and building upon it or hearing another suggestions at a meeting.here there was nothing of that nature.individuals can not be joint inventors if they are completely ignorant of what each other has done until years after their individual efforts.they can not be totally independent of each other and be joint inventors.
a primary focus of section has thus always been on collaboration and joint behavior.a person must contribute to the conception of the claimed invention to qualify as a joint inventor.eli lilly aradigm.yet,each contributor need not have their own contemporaneous picture of the final claimed invention in order to qualify as joint inventors.see fina oil chem.ewen,one need not alone conceive of the entire invention,for this would obviate the concept of joint invention.rather,the qualitative contribution of each collaborator is the inventor must contribute to the joint arrival at a definite and permanent idea of the invention as it will be used in practice.burroughs wellcome barr labs.the interplay between conception and collaboration requires that each engage with the other to contribute to a joint conception.
inventorship is a question of law that we review without deference.ethicon,surgical.we review the underlying findings of fact for clear error.see hess advanced cardiovascular.
vanderbilt raises two arguments on appeal.first,vanderbilt argues that its disclosure of the vanderbilt structural features led to glaxo france identification of the molecule incorporating the same molecular scaffold.in this regard,the gist of vanderbilt case is that labaudiniere could only have identified by using the vanderbilt structural features.second,vanderbilt alleges that the key modification to that yielded tadalafil was the addition of an substituent on the phenyl ring based upon the work of the vanderbilt scientists.
there is no dispute raised between the parties regarding the district court finding that labaudiniere at glaxo france identified as a lead compound for research regarding inhibition.thus,as all relevant contact between the vanderbilt scientists and glaxo occurred at glaxo,vanderbilt attempts to piece together sufficient facts to demonstrate that the vanderbilt structural features must have been used by labaudiniere to identify.as vanderbilt argument is based largely upon criticizing icos evidence regarding how was recognized,we first review glaxo version of the story.
icos contends that labaudiniere independently discovered the compounds to be tested for inhibition through his knowledge of and their vasorelaxation effect.this theory can be found in a paper received by the journal of medicinal chemistry on february,entitled the discovery of tadalafil a novel and highly selective inhibitor.according to glaxo,labaudiniere became aware of the vasorelaxation effect of from his review of two references a article in the european journal of pharmacology the koe article and a may article in the journal of pharmacology and experimental therapeutics the elgoyhen article.glaxo claims that labaudiniere identified two compounds,and,in march as potential inhibitors.labaudiniere then searched an internal database in april with the betacarboline core structure of these two molecules and his search yielded.glaxo internal pde v inhibitors project annual report for the year ending confirms this story.
vanderbilt takes issue with glaxo story because glaxo internal testing records indicate that was first tested by glaxo on april.the elgoyhen article was not published until may.as the district court found,could not have been identified based upon the elgoyhen reference.
at trial,icos backed away from the elgoyhen story and instead argued that labaudiniere took from another glaxo program and tested it on march and,for inhibition.according to icos,labaudiniere undertook substructure searches using the tetrahydro scaffold of,based upon the impressive inhibition results and his knowledge from the koe article,and identified,among other compounds.icos points to the large number of tetrahydro tested between march and july to support its theory.
icos also points to glaxo documents to corroborate various details of its story.for example,the minutes of a glaxo cardiovascular research management committee meeting in april describe as a compound used in a different study.in the june minutes,the same committee noted that displayed a high inhibition activity and noted that glaxo was starting a program testing analogs.at the same meeting,was identified as a new inhibitor.
icos also points to testimony of labaudiniere and daugan to corroborate its theory on the identification of.labaudiniere testified that he did not have any knowledge about the vanderbilt scientists research until june,he did not consider ibmx as a starting point for his work on inhibitors,and he was not aware of anyone at glaxo france using data relating to ibmx analogs or trying to develop inhibitors that would resemble cgmp.daugan confirmed his recollection matches that of labaudiniere.in sum,icos argues that vanderbilt case fails for lack of evidence of any joint collaboration on the invention since neither of the glaxo france scientists had any knowledge of the work of the vanderbilt scientists when they did their work relating to the discovery of tadalafil.
vanderbilt argues a different view of the same facts.first,vanderbilt points out that is never identified in any glaxo documents as a analog.vanderbilt also argues that a substructure search would not yield because no documents demonstrate that glaxo identified the structure in as significant until october.finally,vanderbilt argues that glaxo lacks credibility as it had previously claimed was identified from a search until that was proven false.in sum,vanderbilt attacks glaxo story based upon missing documentary evidence.
vanderbilt instead proposes that labaudiniere reviewed the february research proposal and conducted a substructure search based upon the vanderbilt ibmx analog.vanderbilt points out that in april,just weeks after receiving the february proposal,glaxo france tested compounds for inhibition.vanderbilt points out a number of structural similarities between the tested compounds and its february research proposal.
vanderbilt second argument is that after the project was assigned to daugan,he added to tadalafil an additional element of the vanderbilt structural features by replacing the pyridine ring in with a combination of a phenyl ring and an methoxy substituent.vanderbilt argues that this modification directly uses the results of the vanderbilt scientists research.icos responds that the modifications were all part of a standard trial and error procedure that would be tried with any molecules of interest.
the only evidence of record regarding glaxo modifications to is the testimony of daugan and labaudieniere.daugan testified that t he first thing he did in this series was explore the replacement of the pyridinyl moiety with other heterocyclic or aromatic moieties.labaudiniere testified that there are a standard group of substitutions or additions that would be tried with any molecules of interest.labaudiniere characterizes the modifications leading to tadalafil as obvious and conducted in a fashion.there is no testimony or documentary evidence demonstrating a link between the vanderbilt scientists and daugan prior to the identification of tadalafil.indeed,vanderbilt admitted in the district court that it had no direct evidence to support its view of the facts instead vanderbilt argued that it need not prove specifically how that occurred,but simply how it logically could have occurred.
vanderbilt challenge to the stated inventorship of the and patents turns on competing claims to inventorship of and to tadalafil.as explained above,vanderbilt admits that no direct evidence supports its claims to joint inventorship.nonetheless,vanderbilt argues that labaudiniere could not have identified as a lead compound independently nor could daugan have identified tadalafil on his own.icos counters vanderbilt arguments with direct evidence supporting labaudiniere claim to sole identification of and with similar direct evidence pointing to daugan independent discovery of tadalafil.
to succeed on its claim to joint inventorship,vanderbilt must prevail by clear and convincing evidence.our precedent has long required proof of misjoinder or nonjoinder of by clear and convincing evidence see eli lilly aradigm,ethicon surgical,hess advanced cardiovascular.the district court correctly concluded that vanderbilt failed to meet its burden.
we find no clear error in the district court factual findings underpinning its determination regarding glaxo identification of.the district court noted that there is a close proximity in time of the relevant events which renders plausible plaintiff theory that glaxo did take note of the vanderbilt ibmx compound and incorporated the vanderbilt structural features into the research it was conducting.vanderbilt icos,d.however,after a thorough review of all of the evidence,the district court concluded the court views plaintiff theory which is devoid of evidence regarding the alleged substructure searches based on the vanderbilt ibmx compound and defendant story which is devoid of the aforementioned foundation equally plausible with respect to the identification of.id.we agree that vanderbilt fails to present clear and convincing evidence to support its argument that the work of the vanderbilt scientists was appropriated by labaudiniere for his substructure search.
as for vanderbilt argument that daugan made use of the vanderbilt scientists research for the modifications to,the district court noted that plaintiff admitted that corbin,francis and konjeti never had any direct communication with daugan regarding this subject matter.id.at.the district court also noted a lack of evidence supporting vanderbilt request for an inference that labaudiniere communicated the vanderbilt structural features to daugan.id.there is nothing in the record to suggest that these factual findings are erroneous.thus,vanderbilt also fails to present clear and convincing evidence to support its argument that the modifications to by daugan made use of the vanderbilt scientists research.
vanderbilt makes much of what it perceives to be an error of law committed by the district court.we agree that the district court opinion contains some erroneous statements regarding the law of joint inventorship and a misunderstanding of the relevance of american bioscience to the facts of this case.these errors,however,do not affect the outcome of this appeal and are therefore harmless in context.when tested by the correct law,the facts of the case still require affirmance.
the district court understood our decision in american bioscience to require that each have an independent conception of the final compound for a chemical invention.the district court ruled that because the vanderbilt structural features constitute no more than a portion of a claimed compound,the vanderbilt scientists can not,as a matter of law,be joint inventors.vanderbilt,d at.the district court hinged this portion of its opinion on the following language from american bioscience 
having in mind specific portions of a claimed compound is not the same as conceiving the compound with all of its components.one must have a conception of the specific compounds being claimed,with all of their component substituents 
at.yet,when this language from american bioscience is reviewed in context,the district court error is clear.
the portion of the opinion quoted by the district court phrased the question under review as whether the district court erred in determining that the fsu scientists were true inventors of the claimed compounds.id.emphasis added.in american bioscience the court was faced with choosing between two competing groups of inventors.
prior to the invention of the compounds at issue in american bioscience,tao,a scientist at florida state university fsu,left fsu to join a group of scientists at american bioscience that were working on similar subject matter.id.at.shortly after tao joined american bioscience,the company filed a patent application that led to the patent in suit,which claimed three taxol analog compounds.the patent named tao and three american bioscience scientists as joint inventors.in the district court,fsu claimed that the patent named the wrong inventors.fsu asserted that three of its scientists,along with tao,were